AR104528A1 - Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
AR104528A1
AR104528A1 ARP160101278A ARP160101278A AR104528A1 AR 104528 A1 AR104528 A1 AR 104528A1 AR P160101278 A ARP160101278 A AR P160101278A AR P160101278 A ARP160101278 A AR P160101278A AR 104528 A1 AR104528 A1 AR 104528A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylcarbonyl
pyridinyl
pyrimidinyl
haloalkyl
Prior art date
Application number
ARP160101278A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104528(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104528A1 publication Critical patent/AR104528A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP160101278A 2015-05-08 2016-05-05 Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas AR104528A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08

Publications (1)

Publication Number Publication Date
AR104528A1 true AR104528A1 (es) 2017-07-26

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101278A AR104528A1 (es) 2015-05-08 2016-05-05 Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (32)

Country Link
US (3) US9708325B2 (enExample)
EP (1) EP3294740B1 (enExample)
JP (1) JP6738352B2 (enExample)
KR (1) KR102690131B1 (enExample)
CN (1) CN107580596B (enExample)
AR (1) AR104528A1 (enExample)
AU (3) AU2016260683B2 (enExample)
BR (1) BR112017023959B1 (enExample)
CA (1) CA2982704C (enExample)
CL (1) CL2017002745A1 (enExample)
CO (1) CO2017009994A2 (enExample)
CR (1) CR20170496A (enExample)
DK (1) DK3294740T3 (enExample)
ES (1) ES2753777T3 (enExample)
HR (1) HRP20191942T1 (enExample)
HU (1) HUE045906T2 (enExample)
IL (2) IL254947B (enExample)
LT (1) LT3294740T (enExample)
MX (2) MX376761B (enExample)
MY (1) MY182353A (enExample)
NZ (2) NZ735648A (enExample)
PE (1) PE20171620A1 (enExample)
PH (1) PH12017502009A1 (enExample)
PL (1) PL3294740T3 (enExample)
PT (1) PT3294740T (enExample)
RS (1) RS59435B1 (enExample)
RU (1) RU2745269C2 (enExample)
SG (1) SG10202108841YA (enExample)
SI (1) SI3294740T1 (enExample)
TW (2) TWI768467B (enExample)
UA (1) UA120450C2 (enExample)
WO (1) WO2016180695A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ735648A (en) 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
WO2018050571A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
CA3091950A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132590A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
JP2008540396A (ja) * 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
PL2978429T3 (pl) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Deazapurynony makrocykliczne do leczenia infekcji wirusowych
BR112017002811B1 (pt) 2014-08-15 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit
NZ735648A (en) * 2015-05-08 2023-06-30 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
SG11201901633WA (en) * 2016-08-29 2019-03-28 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
US9708325B2 (en) 2017-07-18
TW201716410A (zh) 2017-05-16
SI3294740T1 (sl) 2019-12-31
BR112017023959A2 (pt) 2018-07-17
AU2016260683A1 (en) 2017-10-12
PE20171620A1 (es) 2017-11-02
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
SG10202108841YA (en) 2021-09-29
PT3294740T (pt) 2019-10-29
HUE045906T2 (hu) 2020-01-28
ES2753777T3 (es) 2020-04-14
RS59435B1 (sr) 2019-11-29
MY182353A (en) 2021-01-20
BR112017023959B1 (pt) 2023-05-02
NZ735648A (en) 2023-06-30
MX393198B (es) 2025-03-19
TWI706954B (zh) 2020-10-11
CN107580596B (zh) 2020-07-14
MX2020010949A (es) 2022-06-16
IL280769B1 (en) 2023-03-01
US20170275286A1 (en) 2017-09-28
EP3294740B1 (en) 2019-09-04
IL280769A (en) 2021-04-29
CL2017002745A1 (es) 2018-05-18
CO2017009994A2 (es) 2018-02-20
HK1247925A1 (zh) 2018-10-05
AU2022204666A1 (en) 2022-07-21
LT3294740T (lt) 2019-11-25
US20160326177A1 (en) 2016-11-10
PH12017502009A1 (en) 2018-03-26
CR20170496A (es) 2017-12-05
NZ775222A (en) 2024-09-27
US10399983B2 (en) 2019-09-03
RU2017142577A (ru) 2019-06-10
AU2020256348B2 (en) 2022-06-16
CA2982704A1 (en) 2016-11-17
CN107580596A (zh) 2018-01-12
IL254947A0 (en) 2017-12-31
AU2020256348A1 (en) 2020-11-12
JP2018515509A (ja) 2018-06-14
DK3294740T3 (da) 2019-11-04
WO2016180695A1 (en) 2016-11-17
HRP20191942T1 (hr) 2020-01-10
UA120450C2 (uk) 2019-12-10
EP3294740A1 (en) 2018-03-21
CA2982704C (en) 2023-10-24
KR20180003612A (ko) 2018-01-09
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
IL280769B2 (en) 2023-07-01
PL3294740T3 (pl) 2020-03-31
MX2017014033A (es) 2018-03-01
MX376761B (es) 2025-03-07
IL254947B (en) 2021-02-28
AU2016260683B2 (en) 2020-10-29
KR102690131B1 (ko) 2024-07-31
TWI768467B (zh) 2022-06-21
JP6738352B2 (ja) 2020-08-12
RU2017142577A3 (enExample) 2019-10-31

Similar Documents

Publication Publication Date Title
AR104528A1 (es) Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR100137A1 (es) Compuestos 4-amino-imidazoquinolina
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR109665A1 (es) Mezclas herbicidas
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR101392A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR094790A1 (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
AR102222A1 (es) Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos
PE20211456A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
AR101222A1 (es) Derivados de piridona
AR101155A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1

Legal Events

Date Code Title Description
FB Suspension of granting procedure